Is there a best TKI for chronic phase CML?

Blood

Volumn 126, Issue 21, 2015, Pages 2370-2375

  Larson, Richard A ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; LEUKEMIA REMISSION; LUNG EDEMA; MULTICENTER STUDY (TOPIC); MUSCLE CRAMP; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; PANCYTOPENIA; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME;

ANIMALS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHILADELPHIA CHROMOSOME; PROTEIN KINASE INHIBITORS;

EID: 84948759161     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-641043     Document Type: Review

References (42)

1. Fava C, Rege-Cambrin G, Saglio G. The choice of first-line chronic myelogenous leukemia treatment. Ann Hematol. 2015; 94(suppl. 2): 123-131.
2. Gambacorti-Passerini C, Piazza R. How I treat newly diagnosed chronic myeloid leukemia in 2015. Amer J Hematol. 2015; 90(2): 156-161.
3. Apperley JF Chronic myeloid leukemia. Lancet. 2015; 385(9976): 1447-1459.
4. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872-884.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version I. 2016. http://www.nccn.org/professionals/physician-gls/pdf/cml.pdf. Accessed September 27, 2015.
6. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol. 2014; 32(5): 415-423.
7. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015; 29(5): 1123-1132.
8. Preudhomme C, Guilhot J, Nicolini FE, et al. the SPIRIT Investigators, and the France Intergroupe des Leucé mies Myéloïdes Chroniques (Fi-LMC): imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363(26): 2511-2521.
9. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28(3): 424-430.
10. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009; 113(19): 4497-4504.
11. Deininger MW, Kopecky KJ, Radich JP, et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized phase II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014; 164(2): 223-232.
12. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012; 120(19): 3898-905.
13. Cortes J, Saglio G, Baccarani M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase trial (DASISION, CA180-056). Blood. 2014; 124(21). Abstract 152.
14. O'Brien SG, Hedgley C, Adams S, et al. Spirit 2: an NCRI randomized study comparing dasatinib with imatinib in patients with newly diagnosed CML. Blood. 2014; 124. Abstract 517.
15. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014; 123(9): 1353-1360.
16. Larson RA, Kim DW, Issaragrisil S, et al. Efficacy and safety of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of ENESTnd. Blood. 2014; 124(21). Abstract 4541.
17. Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015; 125(18): 2771-2778.
18. Brümmendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015; 168(1): 69-81.
19. Lipton JH, Chuah C, Guerci-Bresler A, et al. Epic: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2014; 124. Abstract 519.
20. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3): 232-238.
21. Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012; 30(35): 4323-4329.
22. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012; 26(9): 2096-2102.
23. Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013; 121(24): 4867-4874.
24. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014; 20(2): 310-322.
25. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014; 123(4): 494-500.
26. Hanfstein B, Müller MC, Hochhaus A. Response-related predictors of survival in CML. Ann Hematol. 2015; 94(suppl. 2): 227-239.
27. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and.10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014; 124(4): 511-518.
28. Deininger MW Molecular monitoring in CML and the prospects for treatment-free remissions: Hematology 2015. Hematology Am Soc Hematol Educ Program. In press.
29. Hughes TP, Hochhaus A, Kantarjian HM, et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily. Haematologica. 2014; 99(7): 1204-1211.
30. Yeung DT, Osborn MP, White DL, et al.; Australasian Leukaemia and Lymphoma Group. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015; 125(6): 915-923.
31. Hochhaus A, Saglio G, Larson RA, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013; 121(18): 3703-3708.
32. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119(5): 1123-1129.
33. Mahon FX Discontinuation of tyrosine kinase therapy in CML. Ann Hematol. 2015; 94(suppl. 2): S187-S193.
34. Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013; 27(7): 1511-1519.
35. Efficace F, Rosti G, Aaronson N, et al. Patient-versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014; 99(4): 788-793.
36. Saußele S, Krauß MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML-Study IV. Blood. 2015; 126(1): 42-49.
37. Valent P, Hadzijusufovic E, Schernthaner G-H, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015; 125(6): 901-906.
38. Hochhaus A, Saglio G, Hughes TP, et al. Longterm benefits and risks of frontline nioitnib vs imatinib for patients with chronic myeloid leukemia in chronic phase: ENESTnd 5-year update. Leukemia, in press.
39. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013; 121(22): 4439-4442.
40. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014; 32(4): 306-311.
41. Conti RM, Padula WV, Larson RA. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015; 94(SUPPL. 2): S249-S257.
42. Larson RA, Conti R, Padula WV, et al. What is the most cost-effective strategy for treating newly diagnosed chronic phase chronic myeloid leukemia (CML) after imatinib loses patent exclusivity? Blood. 2014; 124. Abstract 738.